PAREXEL REGULATORY EXPERT VOTED PRESIDENT-ELECT OF DRUG INFORMATION ASSOCIATION

BOSTON, MA, July 22, 2003 — PAREXEL International Corporation (Nasdaq: PRXL), today announced that Alberto Grignolo, PhD, has been named President-elect of the Drug Information Association (DIA) Board of Directors as a result of a vote of the DIA membership.

Dr. Grignolo is President of PAREXEL's Worldwide Regulatory Affairs Services. For two decades, he has been an active and prolific DIA member, serving as Chair of the Regulatory Affairs Track for several DIA Annual Meetings. He has co-organized numerous DIA workshops and sessions whose topics include Key FDA Meetings, Global Registration, the Common Technical Document, Good Clinical Practices, and human research protections. Additionally, Dr. Grignolo has served on the DIA Steering Committee of the Americas and is the current Chair of the Global Marketing Committee. For many years he has been a popular instructor on the DIA Regulatory Affairs Training Course faculty, and has been a member of the DIA Board of Directors since 2000.

"With Dr.Grignolo’s international management experience, his lengthy association with DIA, and his unwavering commitment to the global regulatory environment, he will undoubtedly bring lasting value to DIA and its members," stated Josef H. von Rickenbach, PAREXEL Chairman and CEO. "We at PAREXEL congratulate Alberto on his well-deserved appointment and anticipate his continued professional success."

PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of sophisticated and innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic data capture (EDC), and electronic diary solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL's integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 58 locations throughout 36 countries around the world, and has approximately 5,100 employees.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects” and similar expressions are intended to identify forward-looking statements. PAREXEL’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; PAREXEL’s dependence on certain industries and clients; PAREXEL’s ability to win new business, manage growth, and attract and retain employees; PAREXEL’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of PAREXEL’s Registration Statement Amendment No. 1 on Form S-3/A, as filed with the Securities and Exchange Commission on May 22, 2003, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent PAREXEL's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing PAREXEL's estimates or views as of any date subsequent to the date of this press release.